Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.

  title={Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.},
  author={Auris O Huen and Alain H. Rook},
  journal={Current opinion in oncology},
  volume={26 2},
PURPOSE OF REVIEW The use of agents which exhibit the ability to potently activate the innate immune response has gained significant interest as therapeutics to treat cancer. We will review the history and the current applications of these agents to treat skin cancer and cutaneous T-cell lymphoma. RECENT FINDINGS Particular attention has been focused upon Toll-like receptor (TLR) agonists, including imidazoquinolines, which can trigger TLR 7 and TLR 8, and cytosine-phosphate-guanine (CpG… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 12 extracted citations

In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology • 2018
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 49 references

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy

E Vacchelli, L Galluzzi, A Eggermont
Oncoimmunology • 2012
View 6 Excerpts
Highly Influenced

Toll-like receptor agonists in cancer therapy

S. Adams
Immunotherapy • 2009
View 13 Excerpts
Highly Influenced

Dermatology, 2nd ed

JL Jorrizzo, RP Rapini, al. et, editors
View 5 Excerpts
Highly Influenced

TLR signaling.

Cell death and differentiation • 2006
View 11 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…